These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27669301)

  • 1. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.
    Fleming BD; Ho M
    Toxins (Basel); 2016 Sep; 8(10):. PubMed ID: 27669301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
    Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy.
    Wang C; Gao W; Feng M; Pastan I; Ho M
    Oncotarget; 2017 May; 8(20):32450-32460. PubMed ID: 27419635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
    Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
    Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study.
    Hashemi Yeganeh H; Heiat M; Kieliszek M; Alavian SM; Rezaie E
    Toxins (Basel); 2021 Oct; 13(11):. PubMed ID: 34822533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
    Gao W; Kim H; Ho M
    PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update.
    Fleming BD; Ho M
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32575752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.
    Gao W; Tang Z; Zhang YF; Feng M; Qian M; Dimitrov DS; Ho M
    Nat Commun; 2015 Mar; 6():6536. PubMed ID: 25758784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3 antibodies: a new therapeutic target for liver cancer.
    Feng M; Ho M
    FEBS Lett; 2014 Jan; 588(2):377-82. PubMed ID: 24140348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
    Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
    J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.
    Hanaoka H; Nagaya T; Sato K; Nakamura Y; Watanabe R; Harada T; Gao W; Feng M; Phung Y; Kim I; Paik CH; Choyke PL; Ho M; Kobayashi H
    Mol Pharm; 2015 Jun; 12(6):2151-7. PubMed ID: 25955255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma.
    Wu T; Song Z; Huang H; Jakos T; Jiang H; Xie Y; Zhu J
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109393. PubMed ID: 36375323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
    Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
    Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Combination: Anti Glypican-3 scFv and Diphtheria Toxin with the Best Flexible Linker.
    Hashemi Yeganeh H; Heiat M; Alavian SM; Rezaei E
    Protein J; 2022 Oct; 41(4-5):527-542. PubMed ID: 36001255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET.
    Fayn S; King AP; Gutsche NT; Duan Z; Buffington J; Olkowski CP; Fu Y; Hong J; Sail D; Baidoo KE; Swenson RE; Cheloha RW; Ho M; Choyke PL; Escorcia FE
    J Nucl Med; 2023 Jul; 64(7):1017-1023. PubMed ID: 36997331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
    Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
    Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
    Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
    Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
    Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
    Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
    Zhou F; Shang W; Yu X; Tian J
    Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
    Phung Y; Gao W; Man YG; Nagata S; Ho M
    MAbs; 2012; 4(5):592-9. PubMed ID: 22820551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.